Cargando…

Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection

Introduction: Helicobacter pylori (H. pylori) eradication can prevent metachronous gastric cancer (MGC) after the performance of an endoscopic resection for early gastric cancer (EGC). However, 50% of infections persist after eradication, and the identification of MGC protective factors is important...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ji Eun, Kim, Tae Jun, Lee, Hyuk, Lee, Yeong Chan, Chung, Hwe Hoon, Min, Yang Won, Min, Byung-Hoon, Lee, Jun Haeng, Kim, Jae J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745470/
https://www.ncbi.nlm.nih.gov/pubmed/35011936
http://dx.doi.org/10.3390/jcm11010193
_version_ 1784630353051254784
author Kim, Ji Eun
Kim, Tae Jun
Lee, Hyuk
Lee, Yeong Chan
Chung, Hwe Hoon
Min, Yang Won
Min, Byung-Hoon
Lee, Jun Haeng
Kim, Jae J.
author_facet Kim, Ji Eun
Kim, Tae Jun
Lee, Hyuk
Lee, Yeong Chan
Chung, Hwe Hoon
Min, Yang Won
Min, Byung-Hoon
Lee, Jun Haeng
Kim, Jae J.
author_sort Kim, Ji Eun
collection PubMed
description Introduction: Helicobacter pylori (H. pylori) eradication can prevent metachronous gastric cancer (MGC) after the performance of an endoscopic resection for early gastric cancer (EGC). However, 50% of infections persist after eradication, and the identification of MGC protective factors is important. The anti-tumor activity of aspirin has been demonstrated, but its efficacy in preventing MGC remains controversial. We evaluated the effect of aspirin on metachronous recurrence in H. pylori-negative patients. Methods: A total of 4351 patients were evaluated between January 2007 and December 2016, and 2151 patients who met the inclusion criteria were analyzed. The primary outcome was the cumulative incidence of MGC after an endoscopic resection for EGC. Results: During a 5-year median follow-up (interquartile range, 3.5–6.2), MGC developed in 176 (7.7%) patients, with a cumulative incidence of 89.4% in aspirin users and 92.7% in non-users; this difference was not statistically significant (p = 0.64). The duration of aspirin uses and the occurrence of MGC in both groups were not significantly different. There was no significant difference between groups when the duration of aspirin use was categorized into ≤1 year (hazard ratio (HR), 0.64; 0.20–2.01, p = 0.45), 1–4 years (HR, 1.35; 0.66–2.76, p = 0.41), and >4 years (HR, 1.17; 0.67–2.03, p = 0.58). Conclusions: Aspirin use was not associated with a lower risk of MGC in H. pylori-negative patients. Further prospective studies are needed.
format Online
Article
Text
id pubmed-8745470
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87454702022-01-11 Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection Kim, Ji Eun Kim, Tae Jun Lee, Hyuk Lee, Yeong Chan Chung, Hwe Hoon Min, Yang Won Min, Byung-Hoon Lee, Jun Haeng Kim, Jae J. J Clin Med Article Introduction: Helicobacter pylori (H. pylori) eradication can prevent metachronous gastric cancer (MGC) after the performance of an endoscopic resection for early gastric cancer (EGC). However, 50% of infections persist after eradication, and the identification of MGC protective factors is important. The anti-tumor activity of aspirin has been demonstrated, but its efficacy in preventing MGC remains controversial. We evaluated the effect of aspirin on metachronous recurrence in H. pylori-negative patients. Methods: A total of 4351 patients were evaluated between January 2007 and December 2016, and 2151 patients who met the inclusion criteria were analyzed. The primary outcome was the cumulative incidence of MGC after an endoscopic resection for EGC. Results: During a 5-year median follow-up (interquartile range, 3.5–6.2), MGC developed in 176 (7.7%) patients, with a cumulative incidence of 89.4% in aspirin users and 92.7% in non-users; this difference was not statistically significant (p = 0.64). The duration of aspirin uses and the occurrence of MGC in both groups were not significantly different. There was no significant difference between groups when the duration of aspirin use was categorized into ≤1 year (hazard ratio (HR), 0.64; 0.20–2.01, p = 0.45), 1–4 years (HR, 1.35; 0.66–2.76, p = 0.41), and >4 years (HR, 1.17; 0.67–2.03, p = 0.58). Conclusions: Aspirin use was not associated with a lower risk of MGC in H. pylori-negative patients. Further prospective studies are needed. MDPI 2021-12-30 /pmc/articles/PMC8745470/ /pubmed/35011936 http://dx.doi.org/10.3390/jcm11010193 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Ji Eun
Kim, Tae Jun
Lee, Hyuk
Lee, Yeong Chan
Chung, Hwe Hoon
Min, Yang Won
Min, Byung-Hoon
Lee, Jun Haeng
Kim, Jae J.
Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection
title Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection
title_full Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection
title_fullStr Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection
title_full_unstemmed Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection
title_short Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection
title_sort aspirin use is not associated with the risk of metachronous gastric cancer in patients without helicobacter pylori infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745470/
https://www.ncbi.nlm.nih.gov/pubmed/35011936
http://dx.doi.org/10.3390/jcm11010193
work_keys_str_mv AT kimjieun aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection
AT kimtaejun aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection
AT leehyuk aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection
AT leeyeongchan aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection
AT chunghwehoon aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection
AT minyangwon aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection
AT minbyunghoon aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection
AT leejunhaeng aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection
AT kimjaej aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection